XNCR - XencorAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $32.09 | Open | $32.10 |
| Volume | 301.4K | Market Cap | 1.788B |
| Yield | Last Dividend |
| Xencor Reports Fourth Quarter and Full Y... | 02/24/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor to Host Fourth Quarter and Full Y... | 02/18/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Aimmune Licenses Exclusive Worldwide Rig... | 02/05/20 |
| BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-t... | |
| Gilead (GILD) Inks License Deal with Xen... | 01/09/20 |
| Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV... | |
| Xencor and Gilead Enter License Agreemen... | 01/08/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor Appoints Dagmar Rosa-Bjorkeson to... | 12/20/19 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor Appoints Allen Yang, M.D., Ph.D.,... | 12/18/19 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Xencor to Present Initial Data from the ... | 11/06/19 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Xencor Reports Third Quarter 2019 Financ... | 11/05/19 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Xencor (XNCR) Reports Q2 Loss, Tops Reve... | 08/06/19 |
| Xencor (XNCR) delivered earnings and revenue surprises of 33.33% and 156.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues... | |
| Along With FDA Clinical Hold Being Lifte... | 05/29/19 |
| No summary available. | |
| Xencor up 8% on Q1 beat | 05/10/19 |
| No summary available. | |
| Xencor up 5% on Q1 beat | 05/10/19 |
| No summary available. | |
| Xencor, Inc. (XNCR) CEO Bassil Dahiyat o... | 05/10/19 |
| Xencor, Inc. (NASDAQ:XNCR) Q1 2019 Earnings Conference Call May 09, 2019 4:30 PM ET Company Participants Charles Liles - Associate Director & Head of ... | |
| Xencor Inc (XNCR) Q1 2019 Earnings Call ... | 05/10/19 |
| XNCR earnings call for the period ending March 31, 2019. | |
| Xencor (XNCR) Beats Q1 Earnings and Reve... | 05/09/19 |
| Xencor (XNCR) delivered earnings and revenue surprises of 220.93% and 86.41%, respectively, for the quarter ended March 2019. Do the numbers hold clue... | |
| Xencor beats by $1.79, beats on revenue | 05/09/19 |
| No summary available. | |
| FDA lifts enrollment suspension on Xenco... | 04/30/19 |
| No summary available. | |
| Healthcare Biotech Stocks Top The Positi... | 03/31/19 |
| No summary available. | |
| Daily Insider Ratings Round Up 3/19/19 | 03/21/19 |
| No summary available. | |
| Cytokinetics and Fibrocell Science among... | 03/20/19 |
| No summary available. | |
| BMO likes Amgen and Gilead in premarket ... | 03/15/19 |
| No summary available. | |
| Xencor started at outperform with $40 st... | 03/15/19 |
| This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the ... | |
| Xencor, Inc. (XNCR) CEO Bassil Dahiyat o... | 02/25/19 |
| No summary available. | |
| Xencor Q4 revenues off 62%; shares down ... | 02/25/19 |
| No summary available. | |
| Xencor beats by $0.17, beats on revenue | 02/25/19 |
| No summary available. | |
| Nomura bearish on Xencor in premarket an... | 02/22/19 |
| No summary available. | |
| FDA suspends enrollment in early-stage s... | 02/20/19 |
| No summary available. | |
| Xencor up 4% on Roche deal | 02/05/19 |
| No summary available. | |
| Positive And Negative Forensic Value Sto... | 02/04/19 |
| No summary available. | |
| Buy rating | 02/25/20 |
| Guggenheim Securities upgrades from Neutral to Buy rating and announces Price Target of $43.00 | |
| Strong Buy rating | 01/30/20 |
| RBC Capital initiates coverage with Outperform rating and announces Price Target of $44.00 | |
| Date | 2020-02-24 (AMC) | Est. (EPS/Rev.) | ($0.41)/ 14.27M |
| Actual (EPS/Rev.) | $-0.47/ $3.52 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
